IL140905A0 - Bioenhanced formulations comprising eprosartan in oral solid dosage form - Google Patents

Bioenhanced formulations comprising eprosartan in oral solid dosage form

Info

Publication number
IL140905A0
IL140905A0 IL14090599A IL14090599A IL140905A0 IL 140905 A0 IL140905 A0 IL 140905A0 IL 14090599 A IL14090599 A IL 14090599A IL 14090599 A IL14090599 A IL 14090599A IL 140905 A0 IL140905 A0 IL 140905A0
Authority
IL
Israel
Prior art keywords
eprosartan
dosage form
solid dosage
oral solid
bioenhanced
Prior art date
Application number
IL14090599A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of IL140905A0 publication Critical patent/IL140905A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL14090599A 1998-07-20 1999-07-20 Bioenhanced formulations comprising eprosartan in oral solid dosage form IL140905A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9341898P 1998-07-20 1998-07-20
PCT/US1999/012396 WO2000004862A2 (en) 1998-07-20 1999-07-20 Bioenhanced formulations comprising eprosartan in oral solid dosage form

Publications (1)

Publication Number Publication Date
IL140905A0 true IL140905A0 (en) 2002-02-10

Family

ID=22238820

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14090599A IL140905A0 (en) 1998-07-20 1999-07-20 Bioenhanced formulations comprising eprosartan in oral solid dosage form
IL140905A IL140905A (he) 1998-07-20 2001-01-15 פורמולציות ביומוגדלות המורכבות מאפרוסרטן בצורת מינון מוצקה דרך הפה

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL140905A IL140905A (he) 1998-07-20 2001-01-15 פורמולציות ביומוגדלות המורכבות מאפרוסרטן בצורת מינון מוצקה דרך הפה

Country Status (16)

Country Link
US (1) US6517871B1 (he)
EP (1) EP1098634A4 (he)
JP (1) JP4575594B2 (he)
KR (1) KR100634953B1 (he)
CN (1) CN1198591C (he)
AU (1) AU763309B2 (he)
BR (1) BR9912145A (he)
CA (1) CA2338256C (he)
HU (1) HUP0103000A3 (he)
IL (2) IL140905A0 (he)
NO (1) NO321117B1 (he)
NZ (1) NZ509378A (he)
PL (1) PL193673B1 (he)
TR (1) TR200100172T2 (he)
WO (1) WO2000004862A2 (he)
ZA (1) ZA200100473B (he)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20020168393A1 (en) * 2001-05-08 2002-11-14 Ryota Sugimoto Implantable medical material and implantable medical device
JP4808960B2 (ja) 2002-05-14 2011-11-02 エフ エム シー コーポレーション 微結晶質セルロース組成物
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
AU2003278422A1 (en) * 2002-10-31 2004-05-25 Ranbaxy Laboratories Limited Amorphous form of losartan potassium
WO2004064834A1 (en) * 2003-01-21 2004-08-05 Ranbaxy Laboratories Limited Co-precipitated amorphous losartan and dosage forms comprising the same
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
US20050220881A1 (en) * 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition
CA2555304C (en) 2004-02-06 2016-06-28 Nicolas Peter Shortis Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
EP1586310B1 (de) * 2004-04-15 2006-12-27 Helm AG Verfahren zur Herstellung von freifliessenden, pulverförmigen Valsartan-Adsorbaten
KR20130028807A (ko) * 2004-05-28 2013-03-19 샐릭스 파마슈티컬스 인코포레이티드 방사선 유발성 장염의 예방, 치료 및 개선 방법
US20060099230A1 (en) * 2004-11-10 2006-05-11 Chin-Chih Chiang Novel formulations of eprosartan with enhanced bioavailability
WO2006076097A2 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CN103948609A (zh) * 2005-08-24 2014-07-30 萨利克斯药品公司 巴柳氮制剂及其生产和应用
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7879382B2 (en) 2005-09-30 2011-02-01 Fmc Corporation Stabilizers and compositions and products comprising same
US20080014263A1 (en) * 2006-07-17 2008-01-17 Glenmark Pharmaceuticals Limited Amorphous eprosartan mesylate and process for the preparation thereof
KR20090049089A (ko) * 2006-09-05 2009-05-15 아스트라제네카 아베 칸데사르탄 실렉세틸을 포함하는 약학 조성물
ES2359377T3 (es) * 2006-10-27 2011-05-23 Fmc Corporation Celulosa microcristalina coprocesada y alcohol de azúcar como excipiente para formulaciones de comprimidos.
EP2076249A2 (en) * 2006-10-27 2009-07-08 FMC Corporation Dry granulation binders, products, and use thereof
EP2295430A3 (en) * 2007-07-25 2011-08-03 Hetero Drugs Limited Crystalline solid of eprosartan acetate
EP2181109A4 (en) * 2007-07-25 2011-08-03 Hetero Drugs Ltd CRYSTALLINE PARTICLES OF EPROSARTAN MESYLATE AND PROCESS FOR PREPARING PURE EPROSARTAN
EP2293781A1 (en) * 2008-04-09 2011-03-16 LEK Pharmaceuticals d.d. Granulation of active pharmaceutical ingredients
EP2153822A1 (en) * 2008-08-13 2010-02-17 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
AR072477A1 (es) * 2008-07-11 2010-09-01 Solvay Pharm Bv Formulacion farmaceutica de eprosartan. uso.
JP2011136908A (ja) * 2009-12-25 2011-07-14 Kyowa Yakuhin Kogyo Kk アンギオテンシンｉｉ受容体拮抗剤を含む固形製剤および固形製剤におけるアンギオテンシンｉｉ受容体拮抗剤の保存安定性向上方法
CA2792273A1 (en) * 2010-03-08 2011-09-15 Ratiopharm Gmbh Dabigatran etexilate-containing pharmaceutical composition
CN103842425B (zh) 2011-10-05 2017-05-24 Fmc有限公司 微晶纤维素和羧甲基纤维素的稳定剂组合物、制备方法和应用
ES2657648T3 (es) 2011-10-05 2018-03-06 Fmc Corporation Composición estabilizadora de celulosa microcristalina y carboximetilcelulosa co-reducida, método para elaborarla y usos
WO2013085810A2 (en) 2011-12-09 2013-06-13 Fmc Corporation Co-attrited stabilizer composition
JO3339B1 (ar) * 2012-09-11 2019-03-13 Shanghai Inst Pharmaceutical Ind شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
US20180344646A1 (en) * 2015-11-25 2018-12-06 Patheon Development Services Inc. Amorphous dispersion granules and oral dosage forms
CN107456445A (zh) * 2016-06-06 2017-12-12 南京卡文迪许生物工程技术有限公司 依普利酮口服固体制剂及其制备方法
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525108B1 (fr) * 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
AU656551B2 (en) * 1990-12-14 1995-02-09 Smithkline Beecham Corporation Angiotensin II receptor blocking compositions
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
FR2746013B1 (fr) * 1996-03-18 1998-05-29 Sanofi Sa Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus
ES2198564T3 (es) * 1996-03-29 2004-02-01 Smithkline Beecham Corporation Dihidrato de eprosartan y un procedimiento para su produccion y formulacion.
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
AR011126A1 (es) * 1997-02-14 2000-08-02 Smithkline Beecham Corp Procedimiento para preparar eprosartano y compuestos intermediarios.
DE19741635A1 (de) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
CA2310028C (en) * 1997-11-17 2008-06-10 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.

Also Published As

Publication number Publication date
PL193673B1 (pl) 2007-03-30
EP1098634A4 (en) 2006-10-25
AU763309B2 (en) 2003-07-17
IL140905A (he) 2013-06-27
JP4575594B2 (ja) 2010-11-04
CA2338256A1 (en) 2000-02-03
HUP0103000A2 (hu) 2002-05-29
TR200100172T2 (tr) 2001-05-21
NO321117B1 (no) 2006-03-20
CA2338256C (en) 2008-09-23
KR20010071990A (ko) 2001-07-31
CN1315853A (zh) 2001-10-03
JP2002521315A (ja) 2002-07-16
NO20010283D0 (no) 2001-01-17
EP1098634A2 (en) 2001-05-16
PL346863A1 (en) 2002-03-11
KR100634953B1 (ko) 2006-10-17
NZ509378A (en) 2003-04-29
NO20010283L (no) 2001-01-19
ZA200100473B (en) 2002-09-23
CN1198591C (zh) 2005-04-27
WO2000004862A3 (en) 2000-05-04
HUP0103000A3 (en) 2002-08-28
BR9912145A (pt) 2001-09-25
WO2000004862A2 (en) 2000-02-03
AU5080799A (en) 2000-02-14
US6517871B1 (en) 2003-02-11

Similar Documents

Publication Publication Date Title
PL346863A1 (en) Bioenhanced formulations comprising eprosartan in oral solid dosage form
EG23943A (en) Flash-melt oral dosage formulation
EG23759A (en) Stable extended release oral dosage composition
SG79255A1 (en) Pharmaceutical formulations
HK1090840A1 (en) Extended release oral dosage composition
HUP0103507A3 (en) Pharmaceutical compositions comprising 2-quinolones
PL354315A1 (en) Cosmetic or pharmaceutical composition in solid form comprising bis-acyl-amides
PL343627A1 (en) Medicinal compositions
GB9923045D0 (en) New oral formulations
GB9817650D0 (en) Oral formulation
GB0015361D0 (en) Improvements in pharmaceutical compositions
GB9925069D0 (en) Oral dosage form
GB9807556D0 (en) Pharmaceutical formulations
GB9805931D0 (en) Pharmaceutical formulations
GB9826392D0 (en) Pharmaceutical formulations
GB9828205D0 (en) Pharmaceutical formulations
GB9823192D0 (en) Pharmaceutical formulations
GB9816558D0 (en) Pharmaceutical formulations
GB9820837D0 (en) Pharmaceutical formulations
GB9817429D0 (en) Pharmaceutical formulations
GB9813452D0 (en) Pharmaceutical formulations
GB9825117D0 (en) Pharmaceutical formulations
IL137209A0 (en) Pharmaceutical compositions comprising disulfiram
IL132006A0 (en) Stable pharmaceuticl oral dosage forms
GB0015360D0 (en) Improvements in pharmaceutical compositions